Obesity (Body Mass Index >30 kg/m2)PRO-FITNCT07113561
Effects of a High-protein Diet and Resistance Training on Fat-mass Loss Maintenance
A study testing High-protein diet and resistance training in people with Obesity (Body Mass Index >30 kg/m2), run by Norwegian University of Science and Technology at 1 site in Norway.
Trial summary
This clinical trial investigates whether a high-protein diet combined with resistance training is more effective than a standard low-calorie diet for maintaining fat mass loss in individuals with obesity. A total of 60 adults with obesity (BMI ≥30 kg/m²) will be randomly assigned at baseline to one of two groups: 1. Read more about this study
- Who is it for?
- Ages 18 to 50 years
- Conditions the study is for
- Obesity (Body Mass Index >30 kg/m2)
- What is being tested?
- High-protein diet and resistance training
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteNorway
- Study dates
- 16 Sep 2025to Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- BMI equal to or above 30
- Sedentary lifestyle (<150 minutes moderate physical activity per week and no habitual resistance training (< once weekly)
- < 2 kg body weight change in the 3 months prior to study commencement
- high motivation for lifestyle change
- not currently enrolled in any other obesity or behavioral change program
Who cannot join
- Previous or planned bariatric surgery
- Current or planned usage of medications or anti-obesity drugs known to influence energy metabolism or appetite
- Diabetes (type 1 and 2)
- Women in menopause or post-menopausal women
- Existing cancer diagnosis
- Renal disease
Show all 10Show fewer
- Substance abuse
- Eating disorders
- Allergies, or intolerances to ingredients in meal packs/supplements intended for use in the study
- Mobility/physical constrains or musculoskeletal issues that could impede participation in the resistance training program
Trial locations and contacts
1 site in 1 country.
About this study
This clinical trial investigates whether a high-protein diet combined with resistance training is more effective than a standard low-calorie diet for maintaining fat mass loss in individuals with obesity.
A total of 60 adults with obesity (BMI ≥30 kg/m²) will be randomly assigned at baseline to one of two groups:
Read more
- A control group receiving a balanced low-calorie diet.
- An intervention group receiving a high-protein, low-calorie diet and supervised resistance training.
All participants will follow their assigned low-energy diets for the first 10 weeks, which constitutes the weight loss phase. The subsequent 42 weeks comprise the weight maintenance phase, where participants will follow an energy-balanced diet adapted to their individual needs and continue in their assigned group.
The intervention group will also complete supervised resistance training three times per week during the first 10 weeks, with continued follow-up throughout the maintenance phase.
Assessments will take place at baseline, week 11, 6 months, and 12 months, and include measurements of fat and lean mass, resting metabolic rate, appetite hormones, glucose metabolism, inflammation, gut microbiota and its metabolites, hedonic appetite, eating behavior, and quality of life and physical function. Participants will also provide food intake records, physical activity dat.
The primary aim is to determine whether the combined high-protein diet and resistance training intervention results in greater long-term fat mass loss and muscle mass preservation than the control diet. Secondary aims include effects on appetite regulation, eating behavior, metabolic health, and patient-reported outcomes.
The study is conducted at NTNU and St. Olavs Hospital in Trondheim, Norway, and registered under the acronym PRO-FIT.
- Conditions
- Obesity (Body Mass Index >30 kg/m2)
- Being tested
- High-protein diet and resistance training, Balanced control diet
- Medical subject headings
- Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
High-protein diet and resistance trainingOther
Participants will consume a low-energy high-protein diet for 10 weeks, and participate in supervised resistance training sessions. They will continue a maintenance diet up until the 1 year mark, with bi-monthly follow ups on diet and exercise.
Balanced control dietOther
Participants will consume a balanced low-energy diet for 10 weeks, and continue a balanced maintenance diet with bi-monthly follow ups up until the 1-year mark No active exercise intervention.
| Study group | Role | What they receive |
|---|---|---|
| High-protein diet and resistance training | Experimental | Intervention group: Participants will undergo a low-calorie high-protein diet for 10 weeks, followed by a maintenance phase up to the 1-year mark. This group will also participate in supervised resistance training sessions. Receives: Other: High-protein diet and resistance training |
| Balanced control diet | Experimental | Control group: Participants will undergo a balanced low-calorie diet for 10 weeks, followed by a maintenance phase up to the 1-year mark. This group will not receive any active exercise intervention. Receives: Other: Balanced control diet |
What is being measured
The primary outcome is the main question the study is designed to answer.
Fat-mass
Fat-mass will be estimated using a dual-energy absorptiometry (DXA, GE Healthcare Lunar).
Measured: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
Secondary outcomes (33)
Body weight and -composition
Body weight and -composition will be estimated with dual-energy absorptiometry (DXA, GE Healthcare Lunar) (primary outcomes) and bioimpedance (InBody 770). Compartments that will be estimated are: total body weight, Fat-mass, fat-free mass, bone mineral density, visceral fat, muscle mass, body water, as well as segmental analysis of body weight and composition.
Measured: From enrollment at baseline , after 10 weeks of weight loss phase, 26 and at 52 weeks.
Resting metabolic rate
Resting metabolic rate will be measured in the fasted state using an indirect calorimetry (Quark RMR, Cosmed).
Measured: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
Leeds food preference questionnaire
Food reward and -preferences will be assessed with the Leeds Food Preference Questionnaire (LFPQ), in the fasted state and immediately after the test meal. The LFPQ is a computerized behavioral task that provides measures of 'explicit liking' and explicit and 'implicit wanting' for sensory and nutrient dimensions of foods using food images.
Measured: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
Dutch Eating Behavior Questionnaire
The Dutch Eating Behavior Questionnaire measures restrained, external and emotional eating. Emotional eating can be divided into two sub-categories: diffuse emotions and clearly labelled emotions. The greater score, the greater external/emotional eating.
Measured: From enrollment at baseline , after 10 weeks of weight loss phase, and at 26 and 52 weeks.
Power of Food Scale
The Power of food scale is a psychometric evaluation that measures an individual's preoccupation with wanting of highly palatable foods. The PFS consists of a 15-item list that measures hedonic hunger (food-related thoughts that are unrelated to homeostatic need). The higher the PFS score, the greater the hedonic hunger.
Measured: From enrollment at baseline , after 10 weeks of weight loss phase, and at 26 and 52 weeks.
Three Factor Eating Questionnaire
The Three Factor Eating Questionnaire measures three different dimensions: restraint, disinhibition, and hunger. The greater score, the stronger is the trait/behavior.
Measured: From enrollment at baseline , after 10 weeks of weight loss phase, and at 26 and 52 weeks.
Ghrelin
Blood will be collected in the fasted state (minute 0), and then at intervals after a standardized breakfast (minute 15, 30, 45, 60, 90, 120 and 150) and analyzed for acylated ghrelin concentrations.
Measured: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
GLP-1
Blood will be collected in the fasted state (minute 0), and then at intervals after a standardized breakfast (minute 15, 30, 45, 60, 90, 120 and 150) and analyzed for total GLP-1 concentrations.
Measured: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
CCK
Blood will be collected in the fasted state (minute 0), and then at intervals after a standardized breakfast (minute 15, 30, 45, 60, 90, 120 and 150) and analyzed for CCK concentrations.
Measured: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
PYY
Blood will be collected in the fasted state (minute 0), and then at intervals after a standardized breakfast (minute 15, 30, 45, 60, 90, 120 and 150) and analyzed for total PYY concentrations.
Measured: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
Insulin
Blood will be collected in the fasted state (minute 0), and then at intervals after a standardized breakfast (minute 15, 30, 45, 60, 90, 120 and 150) and analyzed for insulin concentrations.
Measured: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
C-peptide
Blood will be collected in the fasted state (minute 0), and then at intervals after a standardized breakfast (minute 15, 30, 45, 60, 90, 120 and 150) and analyzed for c-peptide concentrations.
Measured: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
Glucose
Blood will be collected in the fasted state (minute 0), and then at intervals after a standardized breakfast (minute 15, 30, 45, 60, 90, 120 and 150) and analyzed for glucose concentrations.
Measured: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
GIP
Blood will be collected in the fasted state (minute 0), and then at intervals after a standardized breakfast (minute 15, 30, 45, 60, 90, 120 and 150). Plasma samples will be stored and analyzed for GIP concentrations depending on additional funding.
Measured: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
Glucagon
Blood will be collected in the fasted state (minute 0), and then at intervals after a standardized breakfast (minute 15, 30, 45, 60, 90, 120 and 150). Plasma samples will be stored and analyzed for glucagon concentrations depending on additional funding.
Measured: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
IL-6
Blood will be collected and plasma samples will be stored and analyzed for IL-6 concentrations depending on additional funding.
Measured: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
TNF-alfa
Blood will be collected and plasma samples will be stored and analyzed for TNF-alfa concentrations depending on additional funding.
Measured: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
CRP
Blood will be collected in the fasted state (minute 0), and analyzed for CRP.
Measured: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
Triglycerides
Blood will be collected in the fasted state (minute 0), and analyzed for triglycerides.
Measured: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
HbA1C
Blood will be collected in the fasted state (minute 0), and analyzed for HbA1C
Measured: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
HDL
Blood will be collected in the fasted state (minute 0), and analyzed for high-density lipoprotein
Measured: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
LDL
Blood will be collected in the fasted state (minute 0), and analyzed for low-density lipoprotein
Measured: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
Total cholesterol
Blood will be collected in the fasted state (minute 0), and analyzed for total choesterol.
Measured: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
Hemoglobin
Blood will be collected in the fasted state (minute 0), and analyzed for hemoglobin.
Measured: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
Gut microbiota
Fecal samples will be collected and comprehensive microbiota profiling using DNA-based sequencing will be performed.
Measured: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
Short-chain fatty-acids
Fecal samples will be collected and acetate, propionate, and butyrate will be quantified by gas chromatography-mass spectrometry (GC-MS)
Measured: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
IWQOL-lite
The Impact of Weight on Quality of Life (IWQOL)-Lite questionnaire will be used to assess obesity-specific quality of life and includes 5 subcategories: physical function, self-compassion, sexual life, public distress and work. In addition, the total quality of life score will be assessed. Higher score, better quality of life.
Measured: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
Short Form-36 (SF-36)
The SF-36, or Short Form 36, is a 36-item questionnaire used to assess a person's self-reported health-related quality of life. It measures eight health concepts: physical functioning, role limitations due to physical health, bodily pain, general health, vitality, social functioning, role limitations due to emotional health, and mental health where a higher score represents better health.
Measured: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
Estimated one-repetition maximum (1RM)
1RM will be calculated using submaximal lifts performed to muscular failure within 4-8 repetitions.
Measured: From enrollment at baseline , after 10 weeks of weight loss phase, and at 26- and 52 weeks.
Patient specific functional Scale
The Patient Specific Functional Scale is a patient-specific instrument. This means that the patient selects activities (three to five) that they have difficulty performing due to their illness or injury, and then rates their ability to perform these activities.
Measured: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
Force development- and peak force
A one-repetition max tests and a force development- and peak force task will be undertaken on a force platform (Kistler, Switzerland) installed on a leg press device.
Measured: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
Subjective appetite
Subjective ratings of appetite (hunger, fullness, desire to eat, and prospective food consumption) will be measured in fasting (minute 0) and then at minute 15, 30, 60, 90, 120 and 150 after the standardized test meal.
Measured: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
Blood pressure
Blood pressure will be measured in units of millimeters of mercury (mmHg)
Measured: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Aug 2025
- Study start16 Sep 2025
- Primary completionJan 2027 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Obesity (Body Mass Index >30 kg/m2)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Norwegian University of Science and Technology
- Sponsor type
- University, hospital or other
- Collaborators
- University of Alabama at Birmingham, University of Leeds, Appetite Control and Energy Balance Research, University of Copenhagen, St. Olavs Hospital
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07113561
- Sponsor's protocol ID
- 592611
- Acronym
- PRO-FIT
- Status last verified
- Oct 2026
- First submitted
- 8 Jul 2025
- Last updated
- 23 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Participant-level data will not be made publicly available due to the sensitive nature of the health-related and biological data collected. Data may be shared with approved collaborators for analyses within the scope of the project, subject to applicable ethical approvals, participant consent, institutional procedures, and data-sharing agreements. Any use beyond the approved project scope will require additional approvals and, where applicable, new participant consent.
Study at a glance
From the registry record, last updated by the sponsor on 23 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of a High-protein Diet and Resistance Training on Fat-mass Loss Maintenance
- ClinicalTrials.gov ID
- NCT07113561
- Acronym / sponsor ID
- PRO-FIT / 592611
- Conditions
- Obesity (Body Mass Index >30 kg/m2)
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Norwegian University of Science and TechnologyUniversity, hospital or other
- Collaborators
- University of Alabama at Birmingham, University of Leeds, Appetite Control and Energy Balance Research, University of Copenhagen, St. Olavs Hospital
- Study start
- 16 Sep 2025 (actual)
- Primary completion
- Jan 2027 (estimated)
- Study completion
- Dec 2027 (estimated)
- First posted
- 8 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This clinical trial investigates whether a high-protein diet combined with resistance training is more effective than a standard low-calorie diet for maintaining fat mass loss in individuals with obesity.
A total of 60 adults with obesity (BMI ≥30 kg/m²) will be randomly assigned at baseline to one of two groups:
- A control group receiving a balanced low-calorie diet.
- An intervention group receiving a high-protein, low-calorie diet and supervised resistance training.
All participants will follow their assigned low-energy diets for the first 10 weeks, which constitutes the weight loss phase. The subsequent 42 weeks comprise the weight maintenance phase, where participants will follow an energy-balanced diet adapted to their individual needs and continue in their assigned group.
The intervention group will also complete supervised resistance training three times per week during the first 10 weeks, with continued follow-up throughout the maintenance phase.
Assessments will take place at baseline, week 11, 6 months, and 12 months, and include measurements of fat and lean mass, resting metabolic rate, appetite hormones, glucose metabolism, inflammation, gut microbiota and its metabolites, hedonic appetite, eating behavior, and quality of life and physical function. Participants will also provide food intake records, physical activity dat.
The primary aim is to determine whether the combined high-protein diet and resistance training intervention results in greater long-term fat mass loss and muscle mass preservation than the control diet. Secondary aims include effects on appetite regulation, eating behavior, metabolic health, and patient-reported outcomes.
The study is conducted at NTNU and St. Olavs Hospital in Trondheim, Norway, and registered under the acronym PRO-FIT.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| High-protein diet and resistance training | Experimental | Other: High-protein diet and resistance trainingIntervention group: Participants will undergo a low-calorie high-protein diet for 10 weeks, followed by a maintenance phase up to the 1-year mark. This group will also participate in supervised resistance training sessions. |
| Balanced control diet | Experimental | Other: Balanced control dietControl group: Participants will undergo a balanced low-calorie diet for 10 weeks, followed by a maintenance phase up to the 1-year mark. This group will not receive any active exercise intervention. |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- BMI equal to or above 30
- Sedentary lifestyle (<150 minutes moderate physical activity per week and no habitual resistance training (< once weekly)
- < 2 kg body weight change in the 3 months prior to study commencement
- high motivation for lifestyle change
- not currently enrolled in any other obesity or behavioral change program
Key exclusion criteria (10 listed)
- Previous or planned bariatric surgery
- Current or planned usage of medications or anti-obesity drugs known to influence energy metabolism or appetite
- Diabetes (type 1 and 2)
- Women in menopause or post-menopausal women
- Existing cancer diagnosis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| High-protein diet and resistance trainingParticipants will consume a low-energy high-protein diet for 10 weeks, and participate in supervised resistance training sessions. They will continue a maintenance diet up until the 1 year mark, with bi-monthly follow ups on diet and exercise. | Other | High-protein diet and resistance training |
| Balanced control dietParticipants will consume a balanced low-energy diet for 10 weeks, and continue a balanced maintenance diet with bi-monthly follow ups up until the 1-year mark No active exercise intervention. | Other | Balanced control diet |
Primary outcome
Fat-mass
Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
Fat-mass will be estimated using a dual-energy absorptiometry (DXA, GE Healthcare Lunar).
33 secondary outcomes
Body weight and -composition
Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, 26 and at 52 weeks.
Resting metabolic rate
Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
Leeds food preference questionnaire
Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
Dutch Eating Behavior Questionnaire
Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 26 and 52 weeks.
Power of Food Scale
Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 26 and 52 weeks.
Three Factor Eating Questionnaire
Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 26 and 52 weeks.
Ghrelin
Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
GLP-1
Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
CCK
Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
PYY
Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
Insulin
Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
C-peptide
Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
Glucose
Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
GIP
Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
Glucagon
Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
IL-6
Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
TNF-alfa
Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
CRP
Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
Triglycerides
Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
HbA1C
Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
HDL
Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
LDL
Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
Total cholesterol
Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
Hemoglobin
Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
Gut microbiota
Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
Short-chain fatty-acids
Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
IWQOL-lite
Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
Short Form-36 (SF-36)
Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
Estimated one-repetition maximum (1RM)
Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 26- and 52 weeks.
Patient specific functional Scale
Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
Force development- and peak force
Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
Subjective appetite
Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
Blood pressure
Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Oct 2026.
- Individual participant dataSharing planned: No. Participant-level data will not be made publicly available due to the sensitive nature of the health-related and biological data collected. Data may be shared with approved collaborators for analyses within the scope of the project, subject to applicable ethical approvals, participant consent, institutional procedures, and data-sharing agreements. Any use beyond the approved project scope will require additional approvals and, where applicable, new participant consent.
Related trials for Obesity (Body Mass Index >30 kg/m2)
Active, not recruiting
Virtual Reality Training on Balance, Postural Stability, Mobility and Quality of Life in Obese Patients
Obesity/Therapy, Obesity (Body Mass Index >30 kg/m2)
Active, not recruitingObservational study
A Consumer Health Study Evaluating the Impact of Pivit on Weight Loss and Appetite in Overweight Individuals
Obesity &Amp;Amp;Amp; Overweight, Obesity (Body Mass Index &Amp;Amp;Amp;Amp;gt;30 kg/m2)
RecruitingPhase 3
Effect of Metformin Use on Weight Loss in Obese, Non-diabetic People (MOWRI)
Obesity and Cardiovascular Risk, Insulin Resistance
Not yet recruitingPhase 4
PHArmaCokinetics of methYLphenidate in Adult Patients With Attention-Deficit /Hyperactivity Disorder
Attention Deficit Hyperactivity Disorder (ADHD), Obesity (Body Mass Index &Amp;Amp;gt;30 kg/m2)
Active, not recruitingObservational study
Sternal Closure in High-BMI Patients: Cable vs Wire
Sternal Wound Complications, Obesity (Body Mass Index >30 kg/m2)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing High-protein diet and resistance training in people with Obesity (Body Mass Index >30 kg/m2), run by Norwegian University of Science and Technology at 1 site in Norway.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 23 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Fat-mass (time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Oct 2026.